Eris Lifesciences Limited, one of India’s leading branded formulations manufacturers, has reported a strong financial and operational performance for the first quarter of FY26. Consolidated revenue grew by 7.4% year-over-year, largely fueled by an 11% rise in its domestic branded formulations business. This key segment also delivered improved profitability, with its EBITDA margin expanding by 155 basis points. Overall, the company’s EBITDA margin rose from 35% to 36%, leading to an EBITDA of INR 277 crore.

The company’s net profit stood at INR 126 crore for the quarter, marking a robust 41% year-on-year growth and a margin of 16.2%.

Eris continues to dominate its core markets, with 12 of its top 25 brands ranking among the top five in their respective therapeutic areas. Additionally, five brands have crossed the INR 100 crore revenue mark. As of June 30, the company’s net debt was approximately INR 2,317 crore.

Commenting on the performance, Amit Bakshi, chairman and managing director of Eris Lifesciences, said, “Our domestic branded formulations business has delivered 11% YoY growth—over 40% higher than the market. Our strategic pivot to high-growth segments is paying off. We are prepared to ensure continued supply in the RHI Penfill segment following the innovator’s exit. Our GLP-1 market entry is progressing as planned, and we aim to be among the first to launch post loss of exclusivity.”

Krishnakumar Vaidyanathan, executive director and COO, added, “We are creating substantial value in the acquired Biocon business, which reported a Q1 operating margin of 30%, up from 19% at acquisition. Our international CDMO business is also scaling well in Western Europe, with several marquee clients onboarded. With 41% growth in PAT and EPS, we’re entering a three-year phase of accelerated EPS and ROCE growth, alongside a sharp reduction in debt, interest, and tax outgo.”

Founded in 2007, Eris is the youngest among India’s top 20 pharmaceutical firms. With branded formulations revenue of over INR 3,000 crore (as per AWACS), the company has established a strong presence across key therapeutic and super-specialty areas such as diabetes, cardiovascular, dermatology, neurology, nephrology, oncology, women’s health, and critical care. Eris manufactures a wide array of prescription drugs across oral, injectable, and biologic formats at six facilities, distributing through 5,000 stockists and over 5,00,000 retail pharmacies.

Over the past five years, Eris has seen its revenue and operating profit multiply 2.6 times. In FY25, the company posted revenue of INR 2,894 crore and has invested INR 4,000 crore over the past three years to diversify its operations across geographies, technologies, and therapy areas.